Kiniksa Pharmaceuticals
Yahoo Finance • 9 days ago
Stock Of The Day In Buy Zone, Leads Industry Despite Supersmall Market
The FDA and European Commission granted orphan drug status to Arcalyst in 2021. Orphan drug designation is given to medicines that target diseases with small patient populations. Regeneron Pharmaceuticals developed Arcalyst, and Kiniksa li... Full story
Yahoo Finance • 11 days ago
Dow Jones Futures: Leading Stocks Stand Tall As Market Bounces; Look For This Bullish Signal
Futures fell as the March jobs report was much stronger than expected. Look for this stock market signal. Tesla tumbled Thursday. Continue Reading... Full story
Yahoo Finance • 11 days ago
AI-Fueled Trio Leads 5 Stocks To Watch Near Buy Points
TJX, Comfort Systems and Equinix are on our stock watchlist this week. Kiniksa Pharmaceuticals and Curtiss-Wright round out the five top stocks to watch. All the five stocks boast strong or solid growth as well as buy points. Continue Rea... Full story
Yahoo Finance • 12 days ago
Dow Jones Futures Fall On Jobs Report Stunner; Stock Market Hasn't Done This Yet
Futures fell as the March jobs report was much stronger than expected. Look for this stock market signal. Tesla tumbled Thursday. Continue Reading... Full story
Yahoo Finance • 13 days ago
Dow Jones Futures Fall With Jobs Report Due; Stock Market Hasn't Done This Yet
The stock market rose strongly for the week, even with oil prices soaring. Investors should look for this signal. Tesla tumbled Thursday on weak deliveries. Continue Reading... Full story
Yahoo Finance • 13 days ago
Dow Jones Futures: Stock Market Resilient As Oil Prices Spike, Tesla Slumps; Jobs Report On Tap
The stock market rose strongly for the week, even with oil prices soaring. Investors should look for this signal. Tesla tumbled Thursday on weak deliveries. Continue Reading... Full story
Yahoo Finance • 15 days ago
Dow Jones Futures: Market Soars As Trump Signals Iran War Exit; Seven Stocks To Watch
President Trump is eyeing an Iran war exit even if the Strait of Hormuz stays closed. Stocks soared, oil prices were mixed. Continue Reading... Full story
Yahoo Finance • 28 days ago
Evommune Stock Sees RS Rating Rise To 91
On Wednesday, Evommune stock earned a positive adjustment to its Relative Strength (RS) Rating, from 87 to 91. Looking For The Best Stocks To Buy And Watch? Start Here This unique rating measures market leadership by showing how a stock's... Full story
Yahoo Finance • 2 months ago
Kiniksa price target raised to $53 from $50 at Wedbush
Wedbush analyst David Nierengarten raised the firm’s price target on Kiniksa (KNSA) to $53 from $50 and keeps an Outperform rating on the shares. The firm notes Arcalyst net product revenue of $202.1M in Q4 and $677.6M for FY25 was in line... Full story
Yahoo Finance • 2 months ago
Shopify, eBay upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Goldman Sachs upgraded eBay (EBAY) to... Full story
Yahoo Finance • 4 months ago
Exploring High Growth Tech Stocks In The US December 2025
As the U.S. stock market continues to reach new heights, with major indices like the S&P 500 setting all-time records, investor sentiment remains buoyant despite recent volatility in tech shares. In this thriving environment, identifying h... Full story
Yahoo Finance • 4 months ago
Why Analysts Favor Kiniksa Pharmaceuticals (KNSA)
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) is one of the most promising mid-cap healthcare stocks under $50. On December 12, Wells Fargo analyst Eva Fortea Verdejo indicated her bullish sentiment and assigned a Buy rating to Kini... Full story
Yahoo Finance • 6 months ago
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth – – ARCALYST 2025 expected net product revenue raised to $670 - $675 million – – KPL-387 granted Orphan Drug Designation for t... Full story
Yahoo Finance • 6 months ago
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
LONDON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardi... Full story
Yahoo Finance • 7 months ago
7 Biotech Stocks Trading At 52-Week Highs - Can The Rally Continue?
(RTTNews) - Patience is a virtue - important in all aspects of life, and especially crucial when it comes to investing. As trading expert Steve Burns once said, "Much of our trading comes down to a battle between our patience and our impul... Full story
Yahoo Finance • 8 months ago
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
LONDON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in fireside chats at the following investor conferences in September: Citi 2025 Biophar... Full story
Yahoo Finance • 8 months ago
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Exhibits High Growth Momentum and Technical Breakout Potential
Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA [https://www.chartmill.com/stock/quote/KNSA]) has become a notable candidate for investors using a high growth momentum strategy combined with technical breakout analysis. This approac... Full story
Yahoo Finance • 8 months ago
KINIKSA PHARMACEUTICALS INTE (NASDAQ:KNSA): A Strong Growth Stock with a Positive Technical Breakout
Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA [https://www.chartmill.com/stock/quote/KNSA]) has appeared as a notable candidate through a screening method that mixes technical and fundamental analysis, specifically looking for sol... Full story
Yahoo Finance • 8 months ago
High Growth Tech Stocks To Watch In The US August 2025
As the U.S. market experiences a mix of record highs and tempered expectations due to recent inflation reports, investors are closely monitoring economic indicators that could influence Federal Reserve policy decisions on interest rates. I... Full story
Yahoo Finance • 8 months ago
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) – An Affordable Growth Stock with Strong Fundamentals and Fair Valuation
Growth investing often focuses on companies with strong revenue and earnings increases, but prices can rise quickly in popular stocks. The "Affordable Growth" strategy balances these factors by finding stocks with good growth potential tha... Full story
